MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Total Shareholders Equity 2011-2026 | DBVT
Annual Total Shareholders Equity DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 140 M | 194 M | 99.3 M | 205 M | 193 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 205 M | 27.4 M | 143 M |
Quarterly Total Shareholders Equity DBV Technologies S.A.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.2 M | 2.87 M | 54 M | 79.1 M | 112 M | 144 M | 164 M | 179 M | 194 M | 212 M | 244 M | 82.1 M | 99.3 M | 117 M | 143 M | 169 M | 205 M | 205 M | 205 M | 205 M | 193 M | - | - | - | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 244 M | 2.87 M | 147 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
50.5 M | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
AstraZeneca PLC
AZN
|
15.6 B | $ 93.52 | -1.2 % | $ 96.9 B |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.52 | -16.3 % | $ 388 M | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.59 | 1.99 % | $ 8.64 B |  Australia |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Biogen
BIIB
|
16.7 B | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
BioNTech SE
BNTX
|
1.37 B | $ 102.17 | 2.32 % | $ 27.2 B | Germany |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 4.25 | 1.67 % | $ 9.25 B |  Israel |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 207.49 | 2.22 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
-15.8 M | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
39.5 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
680 M | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
518 M | - | - | $ 1.01 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
728 M | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Celldex Therapeutics
CLDX
|
747 M | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Cellectis S.A.
CLLS
|
309 M | $ 4.22 | -4.2 % | $ 116 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 29.43 | 6.09 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 9.66 | 2.28 % | $ 1.53 B | Britain |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
466 M | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Athersys
ATHX
|
16.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
1.32 B | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
Abeona Therapeutics
ABEO
|
14.8 M | $ 5.14 | -1.06 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.93 B | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.33 B | $ 632.29 | 0.09 % | $ 47.9 B | USA |
 |
ADiTx Therapeutics
ADTX
|
497 K | $ 0.81 | 1.96 % | $ 10.7 K | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.7 | 2.27 % | $ 17 M | USA |